However, TP53 mutation is enriched in patients with hematologic malignancies without DTA (DNMT3A, TET2, and ASXL1) mutation [52], which suggests that leukemogenesis by TP53 mutation is somewhat different from that caused by DTA mutations. The gene discussed is TP53; the disease is hematologic disorder.